The DeepMind, Google Health and Cancer Research UK breast cancer screening study was published in Nature on 2020-01-01.
Resolved true The record shows it happened or was so.
Factual: Statements about the present or the past, checked against the record: did they hold up?
The second judge would not resolve this claim; the verdict shown is the first judge's.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
True: Nature's record shows the DeepMind / Google Health / Cancer Research UK (with Imperial College and NHS partners) breast cancer screening AI paper (McKinney et al., 'International evaluation of an AI system for breast cancer screening') published online on 1 January 2020. A later print issue date does not count against the claim. Mostly true: published in Nature within a day of 2020-01-01 (time-zone difference), or one listed collaborator is described slightly differently. Mixed: not applicable to a single dated event except where the venue is right and the date is materially off. Mostly false: published in Nature but online on a clearly different date. False: not published in Nature, or no such study exists.
Set before the research began.
Evidence (4)
-
E1 International evaluation of an AI system for breast cancer screening - Nature Nature (Springer Nature) · 1 January 2020 Own record
“McKinney, S.M., Sieniek, M., Godbole, V. et al. International evaluation of an AI system for breast cancer screening. Nature 577, 89–94 (2020).”
-
E2 Artificial intelligence could help to spot breast cancer | Imperial News | Imperial College London Imperial College London · 1 January 2020
“The international team behind the study, which includes researchers from Google Health, DeepMind, Imperial College London, the NHS and Northwestern University in the US, designed and trained an artificial intelligence (AI) model on mammography images from almost 29,000 women.”
-
E3 Artificial intelligence could help to spot breast cancer | Imperial News | Imperial College London Imperial College London · 1 January 2020
“‘International evaluation of an artificial intelligence system to identify breast cancer in screening mammography’ by Scott Mayer McKinney et al. is published in Nature.”
-
E4 Using AI to improve breast cancer screening Google (blog.google) · 1 January 2020 Own record
“Today, we’re sharing our initial findings, which have been published in Nature.”
Reasoning
Nature's article page (E1), dated 2020-01-01, cites McKinney et al., 'International evaluation of an AI system for breast cancer screening', Nature 577, 89–94 (2020). The online date rests on the article page's 2020-01-01 date rather than on its quoted citation, which gives only the year [E1]. Imperial College London's independent news report, also dated 2020-01-01, says the McKinney et al. paper "is published in Nature" (E3). It names Google Health, DeepMind, Imperial and the NHS in the study team (E2), and Google's same-day post says the findings were published in Nature "today" (E4). Together these support online publication in Nature on 1 January 2020. The criteria say a later print issue date does not count against the claim.
Cite this claim
Demis Hassabis, “The DeepMind, Google Health and Cancer Research UK breast cancer screening study was published in Nature on 2020-01-01.” (said 1 January 2020). Verdict: resolved true. Reliability API, claim c_210732426d2b, method 0.1.0+c876030c, dataset release v1.1.2. https://epistacklabs.com/claims/c_210732426d2b
This claim is in dataset release v1.1.2, with the same verdict.
Reply to this claim
More factual claims by Demis Hassabis
-
Mostly true
“what’s important about them is their 3D structure.”
A protein's 3D structure is what determines, or partially determines, its function.
-
Resolved true
“So over 3 million scientists are now using AlphaFold.”
-
Resolved true
“Only about 10% of drugs actually get through all the clinical stages.”
Only about 10% of drugs get through all the clinical stages.
-
Mostly true
“The AlphaFold Server is empowering non-commercial researchers globally to harness this technology, accelerating their ability to formulate and test new hypotheses.”
-
Mostly true
“Our AlphaProteo model can design novel, high-strength protein binders that target diverse molecules – including those associated with cancer and diabetes.”
Verdicts are made automatically; how verdicts are made.